Patents by Inventor William Querbes

William Querbes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Methods for Inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
    Publication number: 20170304446
    Abstract: The invention relates to RNAi agents, e.g. double-stranded RNAi agents, targeting the HAO1 gene, and method of using such RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1. Described herein are double-stranded RNAi agents which inhibit the expression of a HA01 gene in a cell, such as a cell within a subject, e.g., a mammal, such as a human having a HAO1 associated disorder, and uses of such double-stranded RNAi agents. In certain aspects of the invention, substantially all of the nucleotides of an iRNA of the invention are modified.
    Type: Application
    Filed: October 9, 2015
    Publication date: October 26, 2017
    Inventors: William Querbes, Kevin Fitzgerald, Brian Bettencourt, Abigail Liebow, David V. Erbe
  • Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
    Patent number: 9771591
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: September 26, 2017
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya
  • APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20170260527
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.
    Type: Application
    Filed: May 17, 2017
    Publication date: September 14, 2017
    Inventors: Kevin Fitzgerald, William Querbes, James Butler, Stephanie Williams, Abigail Liebow, Gregory Hinkle, Martin Maier, Stuart Milstein, Satyanarayana Kuchimanchi, Muthiah Manoharan
  • Compositions and methods for inhibiting expression of the ALAS1 gene
    Patent number: 9631193
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: April 25, 2017
    Assignees: ALNYLAM PHARMACEUTICALS, INC., ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Brian Bettencourt, Kevin Fitzgerald, William Querbes, Makiko Yasuda, Robert J. Desnick
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
    Publication number: 20160244766
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.
    Type: Application
    Filed: October 3, 2014
    Publication date: August 25, 2016
    Applicants: ALNYLAM PHARMACEUTICALS, INC., ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Brian Bettencourt, Kevin Fitzgerald, William Querbes, Robert J. Desnick, Makiko Yasuda
  • ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20160186180
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Application
    Filed: March 14, 2016
    Publication date: June 30, 2016
    Inventors: Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya
  • COMPOSITIONS AND METHODS FOR INCREASING ERYTHROPOIETIN (EPO) PRODUCTION
    Publication number: 20160177313
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting one or more EGLN genes, EGLN1, EGLN2 and/or EGLN3 and methods of using such dsRNA compositions to inhibit expression of these genes.
    Type: Application
    Filed: October 19, 2015
    Publication date: June 23, 2016
    Inventors: William G. Kaelin, JR., Victor Kotelianski, William Querbes, Brian Bettencourt
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
    Publication number: 20160115476
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.
    Type: Application
    Filed: July 31, 2015
    Publication date: April 28, 2016
    Applicants: ALNYLAM PHARMACEUTICALS, INC., ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Brian Bettencourt, Kevin Fitzgerald, William Querbes, Robert J. Desnick, Makiko Yasuda
  • Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
    Patent number: 9322018
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: April 26, 2016
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya
  • PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20160017335
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the PCSK9 gene, and methods of using such RNAi agents to inhibit expression of PCSK9 and methods of treating subjects having a lipid disorder, such as a hyperlipidemia.
    Type: Application
    Filed: December 5, 2013
    Publication date: January 21, 2016
    Inventors: Anna Borodovsky, Rajeev G. Kallanthottathil, Kevin Fitzgerald, Maria Frank-Kamenetsky, William Querbes, Martin Maier, Klaus Charisse, Satyanarayana Kuchimanchi, Muthiah Manoharan, Stuart Milstein
  • Compositions and methods for increasing erythropoietin (EPO) production
    Patent number: 9193973
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting one or more EGLN genes, EGLN1, EGLN2 and/or EGLN3 and methods of using such dsRNA compositions to inhibit expression of these genes.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: November 24, 2015
    Assignees: Alynylam Pharmaceuticals, Inc., Dana-Farber Cancer Institute
    Inventors: William G. Kaelin, Jr., Victor Kotelianski, William Querbes, Brian Bettencourt
  • Compositions and methods for inhibiting expression of the ALAS1 gene
    Patent number: 9133461
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 15, 2015
    Assignees: Alnylam Pharmaceuticals, Inc., Icahn School of Medicine at Mount Sinai
    Inventors: Brian Bettencourt, Kevin Fitzgerald, William Querbes, Robert J. Desnick, Makiko Yasuda
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
    Publication number: 20150111841
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.
    Type: Application
    Filed: April 10, 2013
    Publication date: April 23, 2015
    Applicant: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Brian Bettencourt, Kevin Fitzgerald, William Querbes, Makiko Yasuda, Robert J. Desnick
  • ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20140179768
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 26, 2014
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Brian Bettencourt, William Querbes, Kevin Fitzgerald, Maria Frank-Kamenetsky, Stuart Milstein, Svetlana Shulga Morskaya
  • COMPOSITIONS AND METHODS FOR INCREASING ERYTHROPOIETIN (EPO) PRODUCTION
    Publication number: 20140024699
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting one or more EGLN genes, EGLN1, EGLN2 and/or EGLN3 and methods of using such dsRNA compositions to inhibit expression of these genes.
    Type: Application
    Filed: December 9, 2011
    Publication date: January 23, 2014
    Applicants: DANA-FARBER CANCER INSTITUTE, ALNYLAM PHARMACEUTICALS, INC.
    Inventors: William G. Kaelin, JR., Victor Kotelianski, William Querbes, Brian Bettencourt
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
    Publication number: 20130281511
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 24, 2013
    Inventors: Brian Bettencourt, Kevin Fitzgerald, William Querbes, Robert J. Desnick, Makiko Yasuda
  • LIPID FORMULATION
    Publication number: 20120101148
    Abstract: The invention features an improved lipid formulation comprising a cationic lipid of formula (A), a neutral lipid, a sterol and a PEG or PEG-modified lipid, where R1 and R2 are independently alkyl, alkenyl or alkynyl, each can be optionally substituted, and R3 and R4 are independently lower alkyl or R3 and R4 can be taken together to form an optionally substituted heterocyclic ring. In one embodiment, R1 and R2 are independently selected from oleoyl, pamitoyl, steroyl, linoleyl and R3 and R4 are methyl. Also disclosed are targeting lipids, and specific lipid formulations comprising such targeting lipids.
    Type: Application
    Filed: January 29, 2010
    Publication date: April 26, 2012
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Akin Aking, William Querbes, Frances M.P. Wong, Joseph R. Dorkin, Xiaojun Qin, William Cantley, Anna Borodovsky, Soma De, Muthiah Manoharan, Muthusamy Jayaraman, Kallanthottathil G. Rajeev
  • DELIVERY OF RNAI CONSTRUCTS TO OLIGODENDROCYTES
    Publication number: 20110118340
    Abstract: The invention provides methods for delivering a double-stranded nbonucleic acid (dsRNA) to the central nervous system of a subject, and particularly, to oligodendrocytes of a subject by localized delivery to the brain, e.g., to the corpus caïlosum. For example, the dsRNA molecules can include a first sequence that is selected from the Sroup consisting of the sense sequences of Tables 8, 10, 13-16, and a second sequence selected from the group consisting of the antisense sequences of Tables 8, 10, and 13-16. The dsRNA molecules can include naturally occurring nucleotides or can include at least one modified nucleotide, such as a 2?-O-methyl modified nucleotide, a nucleotide comprising a 5?-phosphorothioate group, or a terminal nucleotide linked to a conjugate group, such as to a cholesteryl derivative or a vitamin E group.
    Type: Application
    Filed: February 6, 2009
    Publication date: May 19, 2011
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Dinah Sah, William Querbes, Pamela Tan, Qingmin Chen